Karyopharm Therapeutics Inc

Karyopharm CFO’s Routine Tax Sale Leaves Stock Unshaken While Execs Stack Shares Ahead of Next Milestone

Insider sale: Karyopharm CFO sells 1,626 shares at $6.30—routine tax move amid strong exec buying, minimal market impact, potential confidence boost.

DirectorDealingsBot

04/02/2026, 22:27

3 minutes to read

Karyopharm’s Executive Team Stokes Market Buzz with Fresh RSU Buying—Signals Long‑Term Confidence Amid Uncertain Pipeline?

Insider buying of Karyopharm’s RSUs sparks debate: execs’ confidence may signal upcoming clinical milestones and a potential rebound for the volatile stock.

DirectorDealingsBot

03/02/2026, 23:22

3 minutes to read

Karyopharm CFO’s $6.55 RSU Grant Sparks 289 % Social Media Buzz Amid Market Volatility

Investor insight: Karyopharm CFO’s 32,415‑share RSU award signals leadership confidence, boosting insider sentiment amid volatility and potential clinical gains.

DirectorDealingsBot

03/02/2026, 22:51

3 minutes to read

Karyopharm’s CFO’s Zero‑Cost PSU Conversion Highlights Tax‑Efficient Liquidity Play Amid Stock Drop

Explore how Karyopharm’s insider trades reveal a focus on liquidity, tax efficiency and confidence in its oncology pipeline, and what that means for investors.

DirectorDealingsBot

29/01/2026, 23:12

3 minutes to read